Feixiang Wu

2.1k total citations
48 papers, 1.5k citations indexed

About

Feixiang Wu is a scholar working on Hepatology, Oncology and Surgery. According to data from OpenAlex, Feixiang Wu has authored 48 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hepatology, 14 papers in Oncology and 13 papers in Surgery. Recurrent topics in Feixiang Wu's work include Hepatocellular Carcinoma Treatment and Prognosis (16 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (8 papers) and Liver Disease Diagnosis and Treatment (5 papers). Feixiang Wu is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (16 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (8 papers) and Liver Disease Diagnosis and Treatment (5 papers). Feixiang Wu collaborates with scholars based in China, United States and Australia. Feixiang Wu's co-authors include Bang‐De Xiang, Liang Ma, Jiazhou Ye, Tao Bai, Jian‐Hong Zhong, Lu‐Nan Qi, Le‐Qun Li, Wen‐Feng Gong, Le‐Qun Li and Ze‐Guang Han and has published in prestigious journals such as The Journal of Immunology, PLoS ONE and Hepatology.

In The Last Decade

Feixiang Wu

47 papers receiving 1.5k citations

Peers

Feixiang Wu
Keisaku Sato United States
Haofeng Ji United States
Kumaravelu Jagavelu India
Anna Moles Spain
Sanae Haga Japan
Li Bai China
Shinya Sato Japan
Xiongxiong Pan China
Sadayuki Hiroi Japan
Yongtao Xiao China
Keisaku Sato United States
Feixiang Wu
Citations per year, relative to Feixiang Wu Feixiang Wu (= 1×) peers Keisaku Sato

Countries citing papers authored by Feixiang Wu

Since Specialization
Citations

This map shows the geographic impact of Feixiang Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feixiang Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feixiang Wu more than expected).

Fields of papers citing papers by Feixiang Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Feixiang Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feixiang Wu. The network helps show where Feixiang Wu may publish in the future.

Co-authorship network of co-authors of Feixiang Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Feixiang Wu. A scholar is included among the top collaborators of Feixiang Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Feixiang Wu. Feixiang Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wu, Feixiang, Yu Huang, Xiao Xiao, et al.. (2025). Smoking promotes the progression of bladder cancer through FOXM1/CKAP2L axis. Journal of Translational Medicine. 23(1). 785–785. 1 indexed citations
2.
Wu, Feixiang, et al.. (2025). A review on antifouling polyamide reverse osmosis membrane for seawater desalination. Environmental Research. 274. 121305–121305. 3 indexed citations
3.
Chen, Yuehui, Quentin Meyer, Chuan Zhao, et al.. (2023). An outstanding NiFe/NF oxygen evolution reaction boosted by the hydroxyl oxides. Electrochimica Acta. 442. 141862–141862. 8 indexed citations
4.
Shi, Jianhong, Lina Liu, Dandan Song, et al.. (2023). TRAF3/STAT6 axis regulates macrophage polarization and tumor progression. Cell Death and Differentiation. 30(8). 2005–2016. 47 indexed citations
5.
Wei, Meng, Jialong Liu, Jingtong Zhai, et al.. (2022). Ubiquitin ligase RNF125 targets PD-L1 for ubiquitination and degradation. Frontiers in Oncology. 12. 835603–835603. 15 indexed citations
6.
Shen, Bo, Feixiang Wu, Jiazhou Ye, et al.. (2019). Crizotinib-Resistant MET Mutations in Gastric Cancer Patients are Sensitive to Type II Tyrosine Kinase Inhibitors. Future Oncology. 15(22). 2585–2593. 4 indexed citations
7.
Mai, Rongyun, Jiazhou Ye, Jie Chen, et al.. (2019). <p>Preoperative aspartate aminotransferase-to-platelet-ratio index as a predictor of posthepatectomy liver failure for resectable hepatocellular carcinoma</p>. Cancer Management and Research. Volume 11. 1401–1414. 42 indexed citations
8.
Qi, Lu‐Nan, Bang‐De Xiang, Feixiang Wu, et al.. (2018). Circulating Tumor Cells Undergoing EMT Provide a Metric for Diagnosis and Prognosis of Patients with Hepatocellular Carcinoma. Cancer Research. 78(16). 4731–4744. 226 indexed citations
9.
Ye, Jiazhou, Rong Liang, Tao Bai, et al.. (2018). RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research. 37(1). 212–212. 46 indexed citations
10.
Zhong, Jian‐Hong, Linghui Pan, Yanyan Wang, et al.. (2017). Optimizing stage of single large hepatocellular carcinoma. Medicine. 96(15). e6608–e6608. 13 indexed citations
11.
Zhang, Wei, Jie Chen, Dong Xie, et al.. (2017). Validated preoperative computed tomography risk estimation for postoperative hepatocellular carcinoma recurrence. World Journal of Gastroenterology. 23(35). 6467–6473. 21 indexed citations
12.
Luo, Honglin, Jie Chen, Tao Luo, et al.. (2017). Downregulation of Macrophage-Derived T-UCR uc.306 Associates with Poor Prognosis in Hepatocellular Carcinoma. Cellular Physiology and Biochemistry. 42(4). 1526–1539. 36 indexed citations
13.
14.
Zhang, Yongquan, Jiazhou Ye, Xing Liu, et al.. (2016). Hepatic resection versus transarterial chemoembolization for patients with Barcelona Clinic Liver Cancer intermediate stage Child-Pugh A hepatocellular carcinoma. Experimental and Therapeutic Medicine. 12(6). 3813–3819. 21 indexed citations
15.
Wu, Guobin, Chao‐Yuan Huang, Shan Huang, et al.. (2014). Primary hepatic non-Hodgkin’s lymphoma with rectal cancer: A case report. Oncology Letters. 9(1). 324–326. 2 indexed citations
16.
Wu, Feixiang, Bang‐De Xiang, Liang Ma, & Jiazhou Ye. (2013). Hepatic resection versus transaterial chemoembolization for BCLC stage B Child-Pugh A HCC patients. Zhonghua gan-dan waike zazhi. 19(1). 23–28. 1 indexed citations
17.
Zhang, Wei, Feixiang Wu, Qi Wang, & Li Li. (2012). [Effect of XPG down-regulation gene expression towards the proliferation of epithelial ovarian cancer cells and its chemosensitivity to platinum].. PubMed. 47(4). 286–91. 1 indexed citations
18.
Ye, Jiazhou, Feixiang Wu, Zhao Yin-nong, Le‐Qun Li, & Xue‐Mei You. (2012). Recurrence after anatomic versus nonanatomic resection for hepatocellular carcinoma: a Meta-analysis. Zhonghua gan-dan waike zazhi. 18(8). 582–588.
19.
Wu, Feixiang, Jinjun Bian, Xuerong Miao, et al.. (2010). Intrathecal siRNA against Toll-like receptor 4 reduces nociception in a rat model of neuropathic pain. International Journal of Medical Sciences. 7(5). 251–259. 83 indexed citations
20.
Wu, Feixiang, Qi Wang, Zhiming Zhang, et al.. (2009). Identifying serological biomarkers of hepatocellular carcinoma using surface-enhanced laser desorption/ionization-time-of-flight mass spectroscopy. Cancer Letters. 279(2). 163–170. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Keisaku Sato Breakdown of academic impact, for papers by Haofeng Ji Breakdown of academic impact, for papers by Kumaravelu Jagavelu Breakdown of academic impact, for papers by Anna Moles Breakdown of academic impact, for papers by Sanae Haga Breakdown of academic impact, for papers by Li Bai Breakdown of academic impact, for papers by Shinya Sato Breakdown of academic impact, for papers by Xiongxiong Pan Breakdown of academic impact, for papers by Sadayuki Hiroi Breakdown of academic impact, for papers by Yongtao Xiao
Rankless by CCL
2026